dc.contributor.author | Semenova, Yuliya![]() |
|
dc.contributor.author | Kalmatayeva, Zhanna![]() |
|
dc.contributor.author | Oshibayeva, Ainash![]() |
|
dc.contributor.author | Mamyrbekova, Saltanat![]() |
|
dc.contributor.author | Kudirbekova, Aynura![]() |
|
dc.contributor.author | Nurbakyt, Ardak![]() |
|
dc.contributor.author | Baizhaxynova, Ardak![]() |
|
dc.contributor.author | Colet, Paolo![]() |
|
dc.contributor.author | Glushkova, Natalya![]() |
|
dc.contributor.author | Ivankov, Alexandr![]() |
|
dc.contributor.author | Sarria-Santamera, Antonio![]() |
|
dc.date.accessioned | 2022-08-12T05:18:41Z | |
dc.date.available | 2022-08-12T05:18:41Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Semenova, Y., Kalmatayeva, Z., Oshibayeva, A., Mamyrbekova, S., Kudirbekova, A., Nurbakyt, A., Baizhaxynova, A., Colet, P., Glushkova, N., Ivankov, A., & Sarria-Santamera, A. (2022). Seropositivity of SARS-CoV-2 in the Population of Kazakhstan: A Nationwide Laboratory-Based Surveillance. International Journal of Environmental Research and Public Health, 19(4), 2263. https://doi.org/10.3390/ijerph19042263 | en_US |
dc.identifier.uri | http://nur.nu.edu.kz/handle/123456789/6576 | |
dc.description.abstract | The data on seroprevalence of anti-SARS-CoV-2 antibodies in Kazakhstani population are non-existent, but are needed for planning of public health interventions targeted to COVID-19 containment. The aim of the study was to estimate the seropositivity of SARS-CoV-2 infection in the Kazakhstani population from 2020 to 2021. We relied on the data obtained from the results from “IN VITRO” laboratories of enzyme-linked immunosorbent assays for class G immunoglobulins (IgG) and class M (IgM) to SARS-CoV-2. The association of COVID-19 seropositivity was assessed in relation to age, gender, and region of residence. Additionally, we related the monitoring of longitudinal seropositivity with COVID-19 statistics obtained from Our World in Data. The total numbers of tests were 68,732 for SARS-CoV-2 IgM and 85,346 for IgG, of which 22% and 63% were positive, respectively. The highest rates of positive anti-SARS-CoV-2 IgM results were seen during July/August 2020. The rate of IgM seropositivity was the lowest on 25 October 2020 (2%). The lowest daily rate of anti-SARS-CoV-2 IgG was 17% (13 December 2020), while the peak of IgG seropositivity was seen on 6 June 2021 (84%). A longitudinal serological study should be envisaged to facilitate understanding of the dynamics of the epidemiological situation and to forecast future scenarios. | en_US |
dc.language.iso | en | en_US |
dc.publisher | International Journal of Environmental Research and Public Health | en_US |
dc.rights | Attribution-NonCommercial-ShareAlike 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/us/ | * |
dc.subject | Type of access: Open Access | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Kazakhstan | en_US |
dc.subject | seropositivity | en_US |
dc.subject | surveillance | en_US |
dc.title | SEROPOSITIVITY OF SARS-COV-2 IN THE POPULATION OF KAZAKHSTAN: A NATIONWIDE LABORATORY-BASED SURVEILLANCE | en_US |
dc.type | Article | en_US |
workflow.import.source | science |
The following license files are associated with this item: